This document presents a method for SAMHSA-compliant LC/MS/MS analysis using Agilent Bond Elut Plexa PCX and Agilent Poroshell 120. The method meets SAMHSA guidelines and provides measurement of linearity, limit of detection (LOD), accuracy and precision, matrix effects, extraction recovery, and overall process efficiency. The method utilizes premier Agilent products including Agilent Bond Elut Plexa PCX mixed-mode polymeric SPE sorbent, Agilent Poroshell 120 EC-C18 2.7 µm superficially porous LC column, Agilent 1200 Infinity LC system, and Agilent 6460 Triple Quadrupole LC/MS system.
The document presents an LC/MS/MS method compliant with US SAMHSA guidelines for the confirmation of initial drug tests. It details a simplified approach that avoids derivatization steps typically required by GC/MS methods, utilizing Agilent Bond Elut Plexa PCX mixed-mode polymeric SPE sorbent and Agilent Poroshell 120 EC-C18 superficially porous LC columns.
The procedure covers sample preparation via base hydrolysis of urine to convert glucuronides back to THCA, followed by extraction using the Plexa sorbent. The method demonstrates linearity, limit of detection (LOD), accuracy, precision, and measurement of matrix effects and extraction recovery. It utilizes an Agilent 6460 Triple Quadrupole LC/MS system with Jet Stream Technology.
The SAMHSA confirmation cutoff concentration for 11-nor-9-carboxy-tetrahydrocannabinol (THCA) is 15 ng/mL.
The method achieves a limit of detection at 10% of the cutoff, which corresponds to 1.5 ng/mL.